Clinical Commissioning Policy: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

Vedolizumab is not recommended to be available as a routinely commissioned treatment option for refractory UC in pre-pubescent children. Access for older children will be provided in line with the NHS England’s Commissioning Medicines for Children in Specialised Services policy.


NHS England